Taxanes in the treatment of advanced breast cancer;Rola taksanów w leczeniu zaawansowanego raka piersi

Nowotwory

Volumn 53, Issue 2, 2003, Pages 176-184

  Krasińska, Liliana ^a   Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Metastatic breast cancer; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; VINCRISTINE;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER STAGING; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HORMONE RESISTANCE; HUMAN; METASTASIS POTENTIAL; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STANDARD;

EID: 0038324290     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Hortobagyi GN. Drug therapy: treatment of breast cancer. N Eng J Med 1998; 339: 974-84.
2. Henderson JC, Allegra JC, Woodcock T i wsp. Randomized trial comparing mitoxantrone with DOX in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560-71.
3. Seidman AD, Reichman BS, Crown JP i wsp. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-59.
4. Seidman AD, Tiersten A, Hudis C i wsp. II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81.
5. Gianni L, Munzone E, Capri G i wsp. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169-75.
6. Reichman BS, Seidman AD, Crown JP i wsp. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
7. Winer E, Berry D, Duggan D i wsp. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALBG 9342. Proc ASCO 1998; 17: 101a (abstrakt).
8. Nabholtz JM, Gelmon K, Bontenbal M i wsp. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
9. Sledge GW Jr, Neuberg D, Ingle J i wsp. Phase II trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc ASCO 1997; 16: 1a (abstrakt).
10. Paridaens R, Biganzoli L, Bruning P i wsp. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18: 724-33.
11. Bishop JF, Dewar J, Toner GC i wsp. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355-64.
12. Trudeau ME, Eisenhauer EA, Higgins BP i wsp. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-28.
13. 2 as first line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996; 74: 650-56.
14. 2 in patients with metastatic breast cancer according to the status of anhracycline resistance. J Clin Oncol 2001; 19: 336-342.
15. Nabholtz J-M, Senn HJ, Bezwoda WR i wsp. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-24.
16. Chan S, Friedrichs K, Noel D i wsp. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-54.16.
17. Taxanes: a review of the mechanism and toxicity of yew (Taxus spp.) alkaloids. Toxicon 2001; 39: 175-85.
18. Amadori D, Frassineti GL, Zoli W i wsp. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. Oncology 1997; 11: 30-3.
19. Gianni L, Munzone E, Capri G i wsp. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
20. Conte PF, Baldini E, Gennari A i wsp. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510-17.
21. Grasselli G, Vigano L, Capri G i wsp. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 2001; 19: 2222-31.
22. Luck HJ, Thomsen C, Untch M i wsp. Multicentric phase III study in first line treatment of advanced breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc ASCO 200; 19: 73a (abstrakt).
23. Jassem J, Pieńkowski T, Płuzanska A i wsp. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-15.
24. Biganzoli L, Cufer T, Bruning R i wsp. Doxorubicin and paclitaxel versus doxorubicin and cyclophospamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20: 3114-21.
25. Biganzoli L, Piccart MJ: The bigger better? Or what we know and what we still need to learn about anthracycline dose per course, dose intensity and cumulative dose in the treatment of breast cancer. Ann Oncol 1997; 8: 1177-82.
26. Carmichael J. UKCCCR trial of epirubicin and cyclophosphamide (EC) versus epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc ASCO 2001; 20: 22a (abstrakt).
27. Milla-Santos A, Milla L, Rallo L i wsp. V. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 2001; 24: 138-42.
28. Viens P, Roche H, Kerbrat P i wsp. Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am J Clin Oncol 2001; 24: 328-35.
29. Muthalib A, Dawis I, Prayogo N i wsp. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer. Jap J Cancer Chem 2000; 27: 498-504.
30. Nabholtz JM, Mackey JR, Smylic M i wsp. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19: 314-32.
31. Bonneterre J, Dieras V, Tubiana-Hulin M i wsp. 6 Cycles of epirubicin/docetaxel (ET) versus 6 cycles of 5FU epirubicin/cyclophospamide (FEC) as first line metastatic breast cancer (MBC) treatment. Proc ASCO 2001; 20: 42a (abstrakt).
32. Nabholtz J-M, Falkson G, Campos D i wsp. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc ASCO 1999; 18: 127a (abstrakt).
33. Mackey JR, Paterson A, Dirix LY i wsp. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2002; 21: 35a (abstrakt).
34. Gianni L, Dombenowsky P, Sledge G i wsp. Cardiac function following combination therapy with Taxol (T) and doxorubicin (A) for advanced breast cancer (ABC). Proc ASCO 1998; 17: 115a (abstrakt).
35. Fountzilas G, Papadimitriou Ch, Dafni U i wsp. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first line chemotherapy in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 2001; 19: 2232-39.
36. Spielmann M, Tubiana-Hulin M, Namer M i wsp. Alternating and sequential administration of docetaxel with fluorouracil, epirubicin and cyclophosphamide have similar safety profiles for metastatic breast cancer. Br J Cancer 2002; 86:692-97.1.
37. Sideman AD, Hades CA, Albanel J i wsp. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-61.
38. Perez EA, Vogel CL, Irwin DH i wsp. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19: 4216-33.
39. Burstein HJ, Manola J, Younger J i wsp. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18: 1212-19.
40. Hainsworth JD, Buris HA, Yardley DA i wsp. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19: 3500-5.
41. Perez EA, Vogel CL, Irwin DH i wsp. Multicenter phase II trial of wekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19: 4216-23.
42. Piccart MJ, Klijn J, Paridaens R i wsp. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-55.
43. Nabholtz J-M, Gelmon K, Bontenbal M i wsp. Multicenter, randomised comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
44. Mamounas E, Brown A, Smith R i wsp. Effect of Taxol intravenous infusion in advanced breat cancer (ABC): results from NSABP B-26 trial comparing 3- and 24-hour infusion of high-dose Taxol. Proc ASCO 1998; 17: 389a (abstrakt).
45. Gianni L, Vigano L, Locatelli A i wsp. Human pharmacokinetic characterization and in vivo study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15
46. Venturini M, Lunardi G, Del Mastro L i wsp. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 2000; 18: 2116-25.
47. Seidman AD, Hudis CA, Albanel J i wsp. Dose-dense therapy with weekly paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-61.
48. Seidman AD, Hochhouser D, Gollub M i wsp. Ninety-six-hour paclitaxel infusions after progression during short time taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877-84.
49. Zielinski C, Beslija S, Cervek J i wsp. Gemeytabine/epirubicin/paclitaxel (GET) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase III trial of the Central European Cooperative Oncology Group (CECOG). Proc ASCO 2001; 20: 53b (abstrakt).
50. Loesch D, Robert N, Asmar L i wsp. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002; 18: 3857-64.
51. Frasci G, D'Aiuto G, Comella P i wsp. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study. Breast Cancer Res Treat 2000; 62: 87-9.
52. Perez EA, Hillman DW, Stella PJ i wsp. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88: 124-31.
53. Kornek GV, Ulrich-Pur H, Penz M i wsp. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 19: 621-7.
54. Sparano JA, O'Neill A, Schaefer PL i wsp. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1 196. J Clin Oncol 2000; 18: 2369-77.
55. Seidman AD, Fornier MN, Esteva FJ i wsp. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 2001; 19: 2587-95.
56. Slamon D, Leyland-Jones B, Shak S i wsp. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. 56. N Engl J Med 2001; 344: 783-92.